Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038822 | 0.86 | KDM4E (0.56) | LIMK2KCNA5ARMEN1KMT2A | |
| SCHEMBL6038594 | 0.85 | PTGDR2 (0.48) | PTGDR2MEN1KMT2ACCR4CCR2 | |
| SCHEMBL6038918 | 0.85 | AR (0.49) | ARMEN1KMT2ACCR2ALDH1A1 | |
| SCHEMBL6039097 | 0.84 | MEN1 (0.48) | KCNA5ARMEN1KMT2ACCR2 | |
| SCHEMBL6038757 | 0.83 | AR (0.47) | KCNA5ARMEN1KMT2ACCR2 | |
| SCHEMBL6039144 | 0.82 | AR (0.60) | ARMEN1KMT2ACCR2ALDH1A1 | |
| SCHEMBL6038954 | 0.81 | KMT2A (0.50) | ARMEN1KMT2ACCR2ALDH1A1 | |
| SCHEMBL6038656 | 0.81 | AR (0.51) | ARMEN1KMT2ACCR2ALDH1A1 | |
| SCHEMBL6038488 | 0.79 | KDM4E (0.64) | MEN1KMT2ATMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL6039119 | 0.77 | PTGDR2 (0.52) | LIMK2PTGDR2MEN1KMT2ACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | LIMK2 3875/4885KCNA5 3374/4885PTGDR2 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.